Chiara Cremolini

List of Publications by Citations

Source: https://exaly.com/author-pdf/2643748/chiara-cremolini-publications-by-citations.pdf
Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

177 papers	5,916 citations	34 h-index	74 g-index
194 ext. papers	7,548 ext. citations	7 avg, IF	5.14 L-index

#	Paper	IF	Citations
177	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. *New England Journal of Medicine*, **2014**, 371, 1609-18	59.2	663
176	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. *Lancet Oncology, The*, **2015**, 16, 1306-15	21.7	593
175	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. *Nature Medicine*, **2015**, 21, 795-801	50.5	557
174	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, **2009**, 27, 2622-9	2.2	368
173	Primary tumor location as a prognostic factor in metastatic colorectal cancer. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	298
172	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. *Lancet Oncology, The*, **2010**, 11, 845-52	21.7	204
171	Quantitative evidence for early metastatic seeding in colorectal cancer. *Nature Genetics*, **2019**, 51, 1113-1122	30.5	164
170	Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. *JAMA Oncology*, **2019**, 5, 343-350	13.4	134
169	Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. *Journal of the National Cancer Institute*, **2011**, 103, 21-30	9.7	131
168	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	126
167	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2017**, 23, 2414-2422	12.9	111
166	First-line chemotherapy for mCRC□ review and evidence-based algorithm. *Nature Reviews Clinical Oncology*, **2015**, 12, 607-19	19.4	106
165	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncology, The*, **2020**, 21, 497-507	21.7	98
164	Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. *International Journal of Cancer*, **2015**, 136, 83-90	7.5	92
163	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. *Oncologist*, **2016**, 21, 988-94	5.7	72
162	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. *BMC Cancer*, **2011**, 11, 247	4.8	61
161	Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. *Annals of Oncology*, **2018**, 29, 924-930	10.3	60

160	Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. *Annals of Oncology* , **2018**, 29, 1528-1534	10.3	58
159	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. *Clinical Cancer Research*, **2018**, 24, 1082-1089	12.9	58
158	Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. *PLoS ONE*, **2013**, 8, e66774	3.7	55
157	Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. *Journal of Clinical Oncology*, **2020**, JCO2001225	2.2	52
156	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. *JAMA Oncology*, **2018**, 4, 529-536	13.4	51
155	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. *Critical Reviews in Oncology/Hematology*, **2015**, 96, 156-66	7	50
154	Prevention and management of adverse events related to regorafenib. *Supportive Care in Cancer*, **2014**, 22, 837-46	3.9	45
153	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. *Journal of Experimental and Clinical Cancer Research*, **2010**, 29, 58	12.8	41
152	Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis. *European Journal of Cancer*, **2015**, 51, 800-7	7.5	40
151	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. *British Journal of Cancer*, **2016**, 114, 30-6	8.7	39
150	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. *JAMA Oncology*, **2019**, 5, 1268-1275	13.4	37
149	Class 1, 2, and 3 -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. *Clinical Cancer Research*, **2019**, 25, 3954-3961	12.9	36
148	Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis. *International Journal of Cancer*, **2013**, 133, 43-57	7.5	36
147	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. *Nature Communications*, **2018**, 9, 4112	17.4	36
146	Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. *Journal of Clinical Oncology*, **2019**, 37, 3099-3110	2.2	35
145	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. *European Journal of Cancer*, **2017**, 73, 74-84	7.5	32
144	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. *Cancer*, **2012**, 118, 1523-32	6.4	32
143	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. *Oncologist*, **2018**, 23, 1178-1187	5.7	31

142	Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. *Oncologist*, **2015**, 20, 1261-5	5.7	29
141	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. *European Journal of Cancer*, **2019**, 118, 121-130	7.5	29
140	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. *Clinical Cancer Research*, **2017**, 23, 4312-4322	12.9	27
139	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. *Oncotarget*, **2015**, 6, 31604-12	3.3	27
138	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. *Scientific Reports*, **2019**, 9, 2858	4.9	26
137	Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. *Critical Reviews in Oncology/Hematology*, **2011**, 78, 243-51	7	26
136	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. *BMC Cancer*, **2020**, 20, 683	4.8	26
135	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. *Radiotherapy and Oncology*, **2015**, 117, 315-21	5.3	24
134	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. *British Journal of Cancer*, **2020**, 123, 403-409	8.7	22
133	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. *Targeted Oncology*, **2014**, 9, 205-14	5	22
132	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study). *ESMO Open*, **2016**, 1, e000111	6	22
131	Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. *British Journal of Cancer*, **2017**, 116, 318-323	8.7	20
130	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. *Pharmacogenomics Journal*, **2019**, 19, 556-563	3.5	20
129	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. *BMC Cancer*, **2017**, 17, 408	4.8	20
128	First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.. *Journal of Clinical Oncology*, **2018**, 36, 3505-3505	2.2	20
127	The landscape of d16HER2 splice variant expression across HER2-positive cancers. *Scientific Reports* , **2019**, 9, 3545	4.9	18
126	and genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. *Oncotarget*, **2018**, 9, 7859-7866	3.3	18
125	Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. *Annals of Oncology*, **2019**, 30, 1969-1977	10.3	17

124	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. *European Journal of Cancer*, **2019**, 109, 175-182	7.5	17
123	Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. *Cancers*, **2020**, 12,	6.6	17
122	First-line therapy for mCRC - the influence of primary tumour location on the therapeutic algorithm. *Nature Reviews Clinical Oncology*, **2017**, 14, 113	19.4	16
121	KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. *Clinical Colorectal Cancer*, **2020**, 19, 219-225	3.8	16
120	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. *Clinical Colorectal Cancer*, **2018**, 17, e395-e414	3.8	16
119	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. *British Journal of Cancer*, **2017**, 117, 315-321	8.7	15
118	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. *European Journal of Cancer*, **2017**, 77, 13-20	7.5	15
117	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer. *ESMO Open*, **2018**, 3, e000403	6	15
116	Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. *Clinical Colorectal Cancer*, **2012**, 11, 71-6	3.8	15
115	CK7 and consensus molecular subtypes as major prognosticators in BRAF mutated metastatic colorectal cancer. *British Journal of Cancer*, **2019**, 121, 593-599	8.7	14
114	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. *Clinical Cancer Research*, **2018**, 24, 784-793	12.9	14
113	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. *European Journal of Cancer*, **2019**, 110, 32-41	7.5	12
112	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. *Clinical Colorectal Cancer*, **2020**, 19, 156-164	3.8	12
111	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. *Pharmacogenomics Journal*, **2019**, 19, 465-472	3.5	11
110	BRAF-mutated metastatic colorectal cancer between past and future. *British Journal of Cancer*, **2015**, 113, 1634-5	8.7	10
109	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. *British Journal of Cancer* , **2018**, 118, 955-965	8.7	10
108	FOLFOXIRI and bevacizumab for metastatic colorectal cancer. *New England Journal of Medicine*, **2015**, 372, 291-2	59.2	10
107	Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.. *Journal of Clinical Oncology*, **2018**, 36, 12007-12007	2.2	10

106	Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. *Expert Review of Clinical Pharmacology*, **2016**, 9, 877-85	3.8	10
105	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. *Clinical Colorectal Cancer*, **2020**, 19, 191-199.e6	3.8	10
104	Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. *Biochemical Pharmacology*, **2019**, 164, 94-105	6	9
103	The Role of Anti-Angiogenics in Pre-Treated Metastatic -Mutant Colorectal Cancer: A Pooled Analysis. *Cancers*, **2020**, 12,	6.6	9
102	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. *Cancer Research and Treatment*, **2017**, 49, 834-845	5.2	9
101	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. *European Journal of Cancer*, **2020**, 138, 1-10	7.5	9
100	How the lab is changing our view of colorectal cancer. *Tumori*, **2016**, 102, 541-547	1.7	9
99	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. *Clinical Colorectal Cancer*, **2019**, 18, e8-e19	3.8	9
98	Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. *ESMO Open*, **2019**, 4, e000489	6	8
97	TAS-102 for the treatment of metastatic colorectal cancer. *Expert Review of Anticancer Therapy*, **2015**, 15, 1283-92	3.5	8
96	Biomarkers and response to bevacizumab--letter. *Clinical Cancer Research*, **2014**, 20, 1056-7	12.9	8
95	Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients. *Current Cancer Drug Targets*, **2010**, 10, 37-45	2.8	8
94	Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. *Molecular Cancer Therapeutics*, **2020**, 19, 2146-2154	6.1	8
93	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. *European Journal of Cancer*, **2021**, 146, 74-83	7.5	8
92	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. *Clinical Colorectal Cancer*, **2019**, 18, e179-e190	3.8	7
91	Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. *ESMO Open*, **2020**, 5, e000698	6	7
90	Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. *Molecular Cancer Therapeutics*, **2016**, 15, 1740-5	6.1	7
89	TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. *Cancers*, **2021**, 13,	6.6	7

88	Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. *Clinical Cancer Research*, **2021**, 27, 1174-1183	12.9	7
87	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. *BMC Cancer*, **2018**, 18, 98	4.8	6
86	Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality.. *JCO Precision Oncology*, **2019**, 3, 1-14	3.6	6
85	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. *ESMO Open*, **2017**, 2, e000241	6	6
84	Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. *Therapeutic Advances in Medical Oncology*, **2009**, 1, 167-81	5.4	6
83	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. *European Journal of Cancer*, **2021**, 146, 145-154	7.5	6
82	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. *Clinical Colorectal Cancer*, **2019**, 18, 116-124	3.8	5
81	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. *European Journal of Cancer*, **2020**, 135, 78-88	7.5	5
80	Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. *Investigational New Drugs*, **2018**, 36, 709-714	4.3	5
79	and genotyping of synchronous colorectal carcinomas. *Oncology Letters*, **2014**, 7, 1532-1536	2.6	5
78	Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. *Pharmacogenomics*, **2010**, 11, 1247-56	2.6	5
77	Robotic-assisted surgery for colorectal liver metastasis: A single-centre experience. *Journal of Minimal Access Surgery*, **2019**,	1.2	5
76	Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 493-501	4.9	5
75	Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. *Nanomaterials*, **2021**, 11,	5.4	5
74	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. *Clinical Cancer Research*, **2021**, 27, 3234-3242	12.9	5
73	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors **2021**, 9,		5
72	Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study. *ESMO Open*, **2021**, 6, 100073	6	5
71	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. *British Journal of Cancer*, **2021**, 124, 183-190	8.7	5

70	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. *European Journal of Cancer*, **2021**, 144, 31-40	7.5	5
69	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. *Clinical Colorectal Cancer*, **2018**, 17, e471-e488	3.8	4
68	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. *Pharmacogenomics Journal*, **2018**, 18, 623-632	3.5	4
67	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. *Cancer*, **2017**, 123, 4506-4514	6.4	4
66	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer **2020**, 8,		4
65	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. *Oncologist*, **2021**, 26, 302-309	5.7	4
64	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. *Journal of the National Cancer Institute*, **2021**,	9.7	4
63	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.. *Journal of Clinical Oncology*, **2022**, JCO2102583	2.2	4
62	Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. *Pharmacogenomics Journal*, **2019**, 19, 455-464	3.5	3
61	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. *European Journal of Cancer*, **2019**, 111, 138-147	7.5	3
60	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 2374-81	6.1	3
59	Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer. *International Journal of Cancer*, **2020**, 146, 2652-2654	7.5	3
58	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. *European Journal of Cancer*, **2020**, 131, 89-97	7.5	3
57	Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?. *Journal of Clinical Oncology*, **2010**, 28, e173-4; author reply e175-6	2.2	3
56	Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. *Expert Opinion on Biological Therapy*, **2011**, 11, 519-31	5.4	3
55	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer.. *European Journal of Cancer*, **2021**, 161, 90-98	7.5	3
54	Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts).. *Journal of Clinical Oncology*, **2018**, 36, 675-675	2.2	3
53	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. *JCO Precision Oncology*, **2020**, 4,	3.6	3

52	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. *PLoS ONE*, **2020**, 15, e0239439	3.7	3
51	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. *European Journal of Cancer*, **2020**, 139, 81-89	7.5	3
50	Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. *ESMO Open*, **2020**, 5, e001001	6	3
49	Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?. *Clinical Medicine Insights: Oncology*, **2020**, 14, 1179554920946693	1.8	3
48	Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells. *Investigational New Drugs*, **2020**, 38, 92-98	4.3	3
47	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. *European Journal of Cancer*, **2021**, 155, 73-84	7.5	3
46	Response. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	2
45	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation. *Journal of Molecular Diagnostics*, **2020**, 22, 685-698	5.1	2
44	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. *Cancers*, **2020**, 12,	6.6	2
43	Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the BRAF, BeCool platform.. *Journal of Clinical Oncology*, **2018**, 36, 639-639	2.2	2
42	What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities. *PLoS ONE*, **2016**, 11, e0159146	3.7	2
41	Skin Toxicity as Predictor of Survival in Refractory Patients with Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. *Cancers*, **2021**, 13,	6.6	2
40	Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial. *Tumori*, **2021**, 107, 353-359	1.7	2
39	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. *British Journal of Cancer*, **2021**, 125, 839-845	8.7	2
38	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. *Cancer Treatment Reviews*, **2021**, 92, 102135	14.4	2
37	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211020547	5.4	2
36	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors **2021**, 9,		2
35	Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer.. *European Journal of Cancer*, **2022**, 165, 116-124	7.5	2

34	The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features.. *Cancer Treatment Reviews*, **2022**, 106, 102382	14.4	2
33	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. *Scientific Reports*, **2020**, 10, 9778	4.9	1
32	Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study.. *Journal of Clinical Oncology*, **2018**, 36, 581-581	2.2	1
31	Universal Pretreatment Genotyping in Fluoropyrimidine Candidates: Still Controversial but With Clear Instructions for Practitioners, at Last!. *JCO Oncology Practice*, **2020**, 16, 801-802	2.3	1
30	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. *European Journal of Cancer*, **2021**, 150, 133-142	7.5	1
29	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. *European Journal of Cancer*, **2021**, 153, 16-26	7.5	1
28	Fast, Direct Dihydrouracil Quantitation in Human Saliva: Method Development, Validation, and Application. *International Journal of Environmental Research and Public Health*, **2022**, 19, 6033	4.6	1
27	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. *International Journal of Cancer*, **2019**, 145, 2082-2090	7.5	0
26	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.. *Oncologist*, **2022**, 27, e29-e36	5.7	0
25	Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.. *Cancer Treatment Reviews*, **2021**, 103, 102326	14.4	0
24	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. *Molecular Cancer Therapeutics*, **2021**, 20, 1153-1160	6.1	0
23	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. *Scientific Reports*, **2021**, 11, 12191	4.9	0
22	Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. *ESMO Open*, **2019**, 4, e000496	6	0
21	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. *Pharmacogenomics Journal*, **2021**, 21, 285-295	3.5	0
20	FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.. *European Journal of Cancer*, **2022**, 167, 23-31	7.5	0
19	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.. *European Journal of Cancer*, **2022**, 168, 34-40	7.5	0
18	Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. *European Journal of Cancer*, **2022**, 170, 64-72	7.5	0
17	TRIBE2 results and toxicity - Authors' reply. *Lancet Oncology, The*, **2020**, 21, e300-e301	21.7	

List of Publications

16	TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply. *Lancet Oncology, The*, **2015**, 16, e578-9	21.7
15	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. *Current Colorectal Cancer Reports*, **2012**, 8, 153-160	1
14	Choosing the right biologic agent in the "continuum-of-care era"a clinical perspective **2013**, 74-85	
13	Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes to predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab in TRIBE trial.. *Journal of Clinical Oncology*, **2018**, 36, 663-663	2.2
12	Histopathologic response and growth patterns of colorectal cancer liver metastases (CRCLM) in patients treated with triplets plus bevacizumab (bev) or anti-EGFRs.. *Journal of Clinical Oncology*, **2018**, 36, 636-636	2.2
11	Clinical significance of enterocyte-specific gene polymorphisms as candidate marker of oxaliplatin-based treatment for metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2018**, 36, 12066-12066	2.2
10	The impact of Th17 cell pathway-related genetic variants in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy.. *Journal of Clinical Oncology*, **2018**, 36, e15578-e15578	2.2
9	Genetic variation in TET3 and survival in metastatic colorectal cancer (mCRC) from FIRE-3, TRIBE, and MAVERICC clinical trials.. *Journal of Clinical Oncology*, **2018**, 36, 3575-3575	2.2
8	Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3.. *Journal of Clinical Oncology*, **2019**, 37, 594-594	2.2
7	Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.. *Journal of Clinical Oncology*, **2019**, 37, 558-558	2.2
6	A still missing piece of the FIRE-3 puzzle. *Lancet Oncology, The*, **2016**, 17, e515	21.7
5	Atypical Mutations in Metastatic Colorectal Cancer.. *JCO Precision Oncology*, **2019**, 3, 1-11	3.6
4	BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases. *JAMA Surgery*, **2018**, 153, 1162-1163	5.4
3	Considerations in the management of younger patients with colorectal cancer.. *Clinical Advances in Hematology and Oncology*, **2021**, 19 Suppl 16, 1-20	0.6
2	Disease characteristics in younger patients with colorectal cancer.. *Clinical Advances in Hematology and Oncology*, **2021**, 19 Suppl 16, 6-9	0.6
1	Considerations in the management of younger patients With colorectal cancer: Q&A.. *Clinical Advances in Hematology and Oncology*, **2021**, 19 Suppl 16, 15-17	0.6